Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008

BMC Research Notes

Peter Feng Wang¹  Joseph AC Delaney²  Jonathan Schelfhout²  David R Nelson³  Teresa L Kauf² 

[1] Global Health Economics and Outcomes Research, Bristol-Myers Squibb Company, New York, New York, USA;Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA;Department Division of Gastroenterology, Hepatology & Nutrition and Clinical and Translational Science Institute, College of Medicine, University of Florida, Gainesville, Florida, USA

关键词: NHANES;    Platelets;    Hepatitis C;    Thrombocytopenia;   

Others  :  1166591
DOI  :  10.1186/1756-0500-5-142

 received in 2011-11-29, accepted in 2012-03-13,  发布年份 2012

【 摘 要 】

Background

Thrombocytopenia is associated with the natural history of hepatitis C virus (HCV) infection and anti-viral therapy. Recent, national estimates of the clinical burden of thrombocytopenia among HCV-infected individuals in the United States are unavailable. Bi-yearly data from the 1999-2000 to 2007-2008 National Health and Nutrition Examination Surveys (NHANES) were used to examine the prevalence of thrombocytopenia among HCV-infected individuals in the United States.

Results

Among 467 HCV-infected individuals in the survey (weighted population = 3,597,039), mean weighted age was 46.7 years (standard deviation = 15.5) and 61.7% were male. Overall, 7.6% met the study definition of TCP at the 150 × 10⁹/L threshold; 4.5%, 2.0%, and 0.8% had platelet counts below 125, 100, and 75 × 10⁹/L, respectively. The 2-year weighted prevalences of thrombocytopenia (150 × 10⁹/L threshold) from 1999-2008 were 4.9%, 8.6%, 6.5%, 4.1%, and 12.9%. The unadjusted biannual time trend (odds ratio) was 1.16 (95% confidence interval = 0.82-1.64). In the two adjusted models, the odds by time ranged from 1.24-1.40, depending on whether the model included demographic or laboratory variables or both, but did not reach statistical significance. Age was positively and significantly related to thrombocytopenia status.

Conclusions

As the HCV-infected population ages, the prevalence of thrombocytopenia is expected to rise. This study provides limited evidence of such an effect at the national level.

【 授权许可】

   
2012 Kauf et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ghany MG, Strader DB, Thomas DL, et al.: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
• [2]Strader DB, Wright T, Thomas DL, et al.: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
• [3]Wang CS, Yao WJ, Wang ST, et al.: Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: Implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004, 39:790-796.
• [4]Yee HS, Currie SL, Darling JM, et al.: Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006, 101:2360-2378.
• [5]Afdhal N, McHutchison J, Brown R, et al.: Thrombocytopenia associated with chronic liver disease. J Hepatol 2008, 48:1000-1007.
• [6]Louie KS, Micallef JM, Pimenta JM, et al.: Prevalence of thrombocytopenia among patients with chronic hepatitis C: A systematic review. J Viral Hepat 2011, 18:1-7.
• [7]Hoffman-La Roche Inc: Pegasys (peginterferon alfa-2a) product information. [http://www.gene.com/gene/products/information/pegasys/pdf/pi.pdf] webcite
• [8]Schering Corporation: PegIntron (Peginterferon alfa-2b) product information. [http://www.spfiles.com/pipeg-intron.pdf] webcite
• [9]Davis GL, Alter MJ, El-Serag H, et al.: Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
• [10]Davis GL, Albright JE, Cook SF: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338.
• [11]Davis GL, Roberts WL: The healthcare burden imposed by liver disease in aging Baby Boomers. Curr Gastroenterol Rep 2010, 12:1-6.
• [12]Wong JB, McQuillan GM, McHutchison JG, et al.: Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90:1562-1569.
• [13]Streiff MB, Mehta S, Thomas DL: Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002, 35:947-952.
• [14]Grant WC, Jhaveri RR, McHutchison JG, et al.: Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005, 42:1406-1413.
• [15]Jacobson IM, Davis GL, El-Serag H, et al.: Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010, 8:924-933.
• [16]Poordad F: Thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007, 26(Suppl 1):5-11.
• [17]McHutchison JG, Dusheiko G, Shiffman ML: Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357:2227-2236.
• [18]Vermehren J, Sarrazin C: New hepatitis C therapies in clinical development. Eur J Med Res 2011, 16:303-314. BioMed Central Full Text
• [19]Brown RS Jr: A pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007, 26(Suppl 1):41-48.
• [20]Centers for Disease Control and Prevention: National Health and Nutrition Examination Survey. [http://www.cdc.gov/nchs/nhanes.htm] webcite